Full bill text rendering is coming soon.
In the meantime, read the full text on Congress.gov ↗.
Funding / Appropriations Top 2
C.W. Bill Young Cell Transplantation Program Reauthorization Funding
Reauthorizes the C.W. Bill Young Cell Transplantation Program under the Public Health Service Act by authorizing $33,009,000 to be appropriated annually for each of fiscal years 2027 through 2031.
- Population Scope Low Directly affects stem cell transplant patients, donors, and cord blood program participants — a small fraction of the U.S. population with serious blood disorders requiring transplantation.
- Budgetary Magnitude Medium Authorizes $33,009,000 per year for FY2027–2031, totaling roughly $165 million over five years in discretionary appropriations.
- Legal / Regulatory Depth Low Amends an existing authorization ceiling with a new dollar figure and end date — a narrow administrative update that changes no substantive duty, right, or prohibition.
- Degree of Discretion Granted Low Sets a funding ceiling with no new rulemaking delegation or expanded agency authority; appropriations remain subject to the normal congressional process.
- Implementation & Enforcement Burden Low Creates no new enforcement mechanism, compliance obligation, or penalty — the provision solely establishes an appropriations authorization level.
- Temporal Commitment Low Authorization expires at the end of FY2031, a hard sunset within ten years that self-terminates unless Congress acts to extend it.
No signal yet
Duration, Sunset, and Review Top 2
Cord Blood Inventory Program Extension Through 2031
Extends the authorization of the cord blood inventory program under the Stem Cell Therapeutic and Research Act of 2005 from its current expiration of 2026 to 2031, allowing the program to continue operating for five additional years.
- Population Scope Low Affects patients relying on cord blood transplants and participating cord blood banks — a narrow specialized population well under 10% of the U.S. population.
- Budgetary Magnitude Low Changes only the program's expiration date without authorizing or appropriating any specific dollar amount.
- Legal / Regulatory Depth Low Substituting '2031' for '2026' in a sunset clause is a narrow administrative date change that creates no new substantive duty, entitlement, or prohibition.
- Degree of Discretion Granted Low Grants no new agency authority or rulemaking power; the date change preserves existing program administration without expanding discretion.
- Implementation & Enforcement Burden Low Imposes no new compliance requirements, penalties, or enforcement infrastructure — the provision solely extends the program's legal lifespan.
- Temporal Commitment Low The extended authorization expires at end of 2031, a fixed endpoint within ten years that self-terminates absent further congressional action.
No signal yet
No possible riders have been surfaced for this bill.
Summary
This bill reauthorizes the C.W. Bill Young Cell Transplantation Program, administered under the Public Health Service Act, by authorizing $33,009,000 per year in appropriations for fiscal years 2027 through 2031. It also extends the cord blood inventory program under the Stem Cell Therapeutic and Research Act of 2005 from 2026 through 2031, ensuring continued federal support for stem cell research, cord blood banking, and related transplantation activities.
AI-generated summary, pending human review.
| Version | Event | Date | User support | Your vote | Roll calls |
|---|---|---|---|---|---|
| Original |
Initial publication
Sep 4, 2025
|
Sep 4, 2025 | No votes yet | — | — |
Log in or create an account to record your vote on this legislation. Results are visible to all visitors.
Funding / Appropriations Top 2
C.W. Bill Young Cell Transplantation Program Reauthorization Funding
Reauthorizes the C.W. Bill Young Cell Transplantation Program under the Public Health Service Act by authorizing $33,009,000 to be appropriated annually for each of fiscal years 2027 through 2031.
- Population Scope Low Directly affects stem cell transplant patients, donors, and cord blood program participants — a small fraction of the U.S. population with serious blood disorders requiring transplantation.
- Budgetary Magnitude Medium Authorizes $33,009,000 per year for FY2027–2031, totaling roughly $165 million over five years in discretionary appropriations.
- Legal / Regulatory Depth Low Amends an existing authorization ceiling with a new dollar figure and end date — a narrow administrative update that changes no substantive duty, right, or prohibition.
- Degree of Discretion Granted Low Sets a funding ceiling with no new rulemaking delegation or expanded agency authority; appropriations remain subject to the normal congressional process.
- Implementation & Enforcement Burden Low Creates no new enforcement mechanism, compliance obligation, or penalty — the provision solely establishes an appropriations authorization level.
- Temporal Commitment Low Authorization expires at the end of FY2031, a hard sunset within ten years that self-terminates unless Congress acts to extend it.
No signal yet
Funding / Appropriations
C.W. Bill Young Cell Transplantation Program Reauthorization Funding
Duration, Sunset, and Review Top 2
Cord Blood Inventory Program Extension Through 2031
Extends the authorization of the cord blood inventory program under the Stem Cell Therapeutic and Research Act of 2005 from its current expiration of 2026 to 2031, allowing the program to continue operating for five additional years.
- Population Scope Low Affects patients relying on cord blood transplants and participating cord blood banks — a narrow specialized population well under 10% of the U.S. population.
- Budgetary Magnitude Low Changes only the program's expiration date without authorizing or appropriating any specific dollar amount.
- Legal / Regulatory Depth Low Substituting '2031' for '2026' in a sunset clause is a narrow administrative date change that creates no new substantive duty, entitlement, or prohibition.
- Degree of Discretion Granted Low Grants no new agency authority or rulemaking power; the date change preserves existing program administration without expanding discretion.
- Implementation & Enforcement Burden Low Imposes no new compliance requirements, penalties, or enforcement infrastructure — the provision solely extends the program's legal lifespan.
- Temporal Commitment Low The extended authorization expires at end of 2031, a fixed endpoint within ten years that self-terminates absent further congressional action.
No signal yet
Duration, Sunset, and Review
Cord Blood Inventory Program Extension Through 2031
Incomplete vote
You have not made a selection on all required items:
Choose Neutral if you prefer not to commit. Leaving without completing will remove all your votes for this bill from the totals.
Maximum recommendations reached
You have already recommended the maximum number of components allowed on this bill. To recommend [new component], choose one of your current recommendations to unselect: